Recent advances in treating multiple myeloma, the second most common blood cancer, and other blood malignancies are providing improved outcomes – and hope – to patients worldwide. But treatment breakthroughs such as the immunotherapy drug teclistamab can lead to potentially lethal side effects, including cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS). These